Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Ciber of Epidemiology and Public Health (CIBERESP), Madrid, Spain
Departament de Salut
2024-01-26T09:45:07Z
2024-01-26T09:45:07Z
2022-05-08
COVID-19 vaccination coverage; SARS-CoV-2; Anti-SARS-CoV-2 herd immunity
Cobertura de vacunación COVID-19; SARS-CoV-2; Inmunidad colectiva anti-SARS-CoV-2
Cobertura de vacunació COVID-19; SARS-CoV-2; Immunitat de grup anti-SARS-CoV-2
The pandemic associated with SARS-CoV-2 is a worldwide public health challenge. The WHO has proposed to achieve 70% COVID-19 vaccination coverage in all countries by mid-2022. Nevertheless, the prevention strategy based on COVID-19 vaccination and other applied prevention measures has not been sufficient to prevent SARS-CoV-2 epidemic waves. This study assessed the vaccination coverage that would be required to establish herd immunity against SARS-CoV-2, taking into account virus transmissibility (Ro values from 1.1 to 10) and COVID-19 vaccination effectiveness. The study found that high percentages of vaccination coverage and high levels of vaccination effectiveness are necessary to block the transmission of Omicron and other SARS-CoV-2 variants with greater infectious capacity. COVID-19 vaccination programs could establish herd immunity against SARS-CoV-2, with Ro values ranging from 3 to 10 and levels of COVID-19 vaccination effectiveness of 70-100%. Factors reducing COVID-19 vaccination effectiveness (emergent variants, infections among vaccinated individuals, high risk individuals) and factors increasing SARS-CoV-2 transmissibility (close settings) increased the percentages of vaccination coverage that would be required to establish herd immunity. Two measures should be implemented to establish herd immunity against SARS-CoV-2: (1) achieve ≥ 90% COVID-19 vaccination coverage in all countries worldwide, and (2) increase the effectiveness of COVID-19 vaccines in preventing Omicron infection to at least 88%.
Article
Published version
English
COVID-19 (Malaltia) - Vacunació; Immunització; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; PUBLIC HEALTH::Health Care (Public Health)::Disease Prevention::Primary Prevention::Immunization::Mass Vaccination::Vaccination Coverage; PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Immunity, Herd; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; SALUD PÚBLICA::atención a la salud (salud pública)::prevención de enfermedades::prevención primaria::inmunización::vacunación masiva::cobertura de vacunación; FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::inmunidad de grupos
MDPI
Vaccines;10(5)
https://doi.org/10.3390/vaccines10050736
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/